mo:re GmbH aus Hamburg | Automation | Biotechnology

Mo:re is building the new gold standard for organoid-based drug develompment

Achievements

Team

Prototype

Users

Partners

Revenue

Investors

What we offer

mo:re is a biotech startup dedicated to revolutionizing the pharmaceutical industry. Founded in 2023 and based in Hamburg, we are on a mission to establish the new gold standard for organoid-based drug development, ultimately aiming to eliminate the need for animal studies. Our innovative lab platform empowers organizations to conduct organoid cell culture studies, offering a cost-effective, faster, and more compliant alternative to traditional animal testing.

Target group

Pharma, Biotechnology

Challenges

Having closed our Seed Funding round, we will begin the commercialization of our product in Q4 2024. For this, our software platform needs to be expanded.

Our Story

A spin-off from QUT in Australia, we incorporated in Hamburg in March 2023. Currently, we are a team of four, all working in full-time, having received >500k€ in pre-seed investment to achieve proof of concept. We are now in the process of closing our seed round with leading VCs.